Actinium Therapy for Late-stage Aggressive Sarcomas

The goal of this clinical trial is to learn about the safety of drug \[Ac225\]RTX-2358 and the diagnostic imaging agent \[Cu64\]LNTH-1363S. Additionally Ratio Therapeutics will learn if \[Ac225\]RTX-2358 drug is effective in treating advanced sarcoma. The main questions the study aims to answer in Phase/Part 1 of the trial are: * Is \[Ac225\]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients. * What is the most tolerable dose of \[Ac225\]RTX-2358 * Does the treatment show effectiveness on advanced sarcoma Participants will: * Take drug \[Ac225\]RTX-2358 once ever

Trial Details

NCT ID
NCT07156565
Phase
PHASE1
Sponsor
Ratio Therapeutics, Inc.
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • [Ac 225]RTX-2358
  • [Cu64]LNTH-1363S
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • New York, New York, United States|40.71427,-74.00597
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • 18 years of age or older.
  • History of relapsed or refractory soft tissue sarcoma.
  • Histological confirmation of sarcoma at any point since diagnosis
  • At least 1 prior treatment regimen

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →